Letter to Patients To: Sufferers and carriers of Huntington’s disease and their families From: Medesis Pharma Corporate Communications Date: Subject: NP03 in development for the treatment of Huntington’s - Lithium orotate - Document - PDFSEARCH.IO

First Page	Meta Content
	Letter to Patients To: Sufferers and carriers of Huntington’s disease and their families From: Medesis Pharma Corporate Communications Date: Subject: NP03 in development for the treatment of Huntington’s Add to Reading List Document Date: 2011-07-25 18:53:25 Open Document File Size: 42,93 KB Share Result on Facebook Company Medesis Pharma / / Continent North America / Europe / / Country France / / Event Analyst Recommendation / / IndustryTerm treatment of Huntington’s disease / pharmaceutical product / drug delivery technology / treatment of bipolar disorder / metal ions / / MedicalCondition diseases / disease / chronic long term treatment / neurodegenerative diseases / Huntington’s disease / bipolar disorder / / Organization Committee for Orphan Medicinal Products / / Position representative / / Product Lithium citrate / / Technology drug delivery technology / / URL www.medesispharma.com / / SocialTag Lithium Lithium pharmacology Pharmacology Treatment of bipolar disorder Mood disorders Pharmaceutical drug Neurodegeneration Bipolar disorder Lithium orotate Chemistry

Letter to Patients To: Sufferers and carriers of Huntington’s disease and their families From: Medesis Pharma Corporate Communications Date: Subject: NP03 in development for the treatment of Huntington’s Add to Reading List